Published December 20, 2022 | Version v1
Dataset Open

Genetically adjusted PSA levels for prostate cancer screening

Creators

  • 1. Stanford University
  • 2. University of California San Francisco
  • 3. National Cancer Institute
  • 4. Vanderbilt University Medical Center
  • 5. Fred Hutchinson Cancer Research Center
  • 6. CHRISTUS Santa Rosa Medical Center Hospital
  • 7. Memorial Sloan Kettering Cancer Center
  • 8. Kaiser Permanente Northern California
  • 9. University of Southern California
  • 10. Icahn School of Medicine at Mount Sinai

Description

Prostate-specific antigen (PSA) screening for prostate cancer remains controversial because it increases overdiagnosis and overtreatment of clinically insignificant tumors. Accounting for genetic determinants of constitutive, non-cancer PSA variation has potential to improve screening utility. We discovered 128 genome-wide significant associations (P<5×10-8) in a multi-ancestry GWAS meta-analysis of 95,768 men and developed a PSA polygenic score (PGSPSA) that explains 9.61% of constitutive PSA variation. Here we provide full GWAS summary statistics for the multi-ancestry meta-analysis and ancestry-stratified summary statistics for ~1.2 million variants used to derive a genome-wide PGSPSA.

Files

PSA_PRScsx_AFR.txt

Files (922.0 MB)

Name Size Download all
md5:cf7785e0dd2e954484a2811c0399f192
781.7 MB Download
md5:09553db334e1717deab6db93f7bb837b
37.0 MB Preview Download
md5:e748812e0d292826d01caf22171ac9b3
36.8 MB Preview Download
md5:53e356b38c3af7f12895e0044a1faa3b
33.7 MB Preview Download
md5:740221a5afce3bfb8fe7831dbd491cdd
32.8 MB Preview Download
md5:3fd545937bd38f21f80af20a34c2f7e1
220 Bytes Download
md5:c7d0649c4f68e19121ef4f253b11385f
900 Bytes Download

Additional details

Related works

Is published in
Preprint: 10.1101/2022.04.18.22273850 (DOI)
Journal article: 10.1038/s41591-023-02277-9 (DOI)